These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 12412171

  • 1. Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and dacarbazine-like chemotherapy regimen followed by extended-field, full-dose radiotherapy: long-term results of the Groupe Ouest et Est des Leucémies et Autres Maladies de Sang H90-A/B Multicenter Randomized Trial.
    Djeridane M, Oudard S, Escoffre-Barbe M, Lacotte-Thierry L, Desablens B, Briére J, Dib M, Cassasus P, Ghandour C, Lamy T, Lejeune F, Simon M, Traullé C, Vigier M, Maisonneuve H, Briére J, Colonna P, Andrieu JM.
    Cancer; 2002 Nov 15; 95(10):2169-79. PubMed ID: 12412171
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
    Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, Herrmann R, Pfreundschuh M, Sieber M, Tesch H, Franke A, Koch P, de Wit M, Paulus U, Hasenclever D, Loeffler M, Müller RP, Müller-Hermelink HK, Dühmke E, Diehl V.
    J Clin Oncol; 2007 Aug 10; 25(23):3495-502. PubMed ID: 17606976
    [Abstract] [Full Text] [Related]

  • 5. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E.
    Cancer; 2000 May 01; 88(9):2142-8. PubMed ID: 10813727
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M, Intergruppo Italiano Linfomi.
    J Clin Oncol; 2005 Dec 20; 23(36):9198-207. PubMed ID: 16172458
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease.
    Viviani S, Bonfante V, Santoro A, Zanini M, Devizzi L, Di Russo AD, Soncini F, Villani F, Ragni G, Valagussa P, Bonadonna G.
    Cancer J Sci Am; 1999 Dec 20; 5(5):275-82. PubMed ID: 10526668
    [Abstract] [Full Text] [Related]

  • 12. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.
    Aleman BM, Raemaekers JM, Tomiŝiĉ R, Baaijens MH, Bortolus R, Lybeert ML, van der Maazen RW, Girinsky T, Demeestere G, Lugtenburg P, Lievens Y, de Jong D, Pinna A, Henry-Amar M, European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group.
    Int J Radiat Oncol Biol Phys; 2007 Jan 01; 67(1):19-30. PubMed ID: 17097834
    [Abstract] [Full Text] [Related]

  • 13. A randomized trial of brief treatment of early- stage Hodgkin lymphoma: Is it effective?
    Hamed RH, Anter AH, Awad IA.
    Hematol Oncol Stem Cell Ther; 2012 Jan 01; 5(1):36-41. PubMed ID: 22446609
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
    Martinelli G, Cocorocchio E, Peccatori F, Zucca E, Saletti PC, Calabrese L, Pastano R, Pruneri G, Mazzetta C, Ghielmini M, Cavalli F.
    Br J Haematol; 2004 Jun 01; 125(5):584-9. PubMed ID: 15147373
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
    Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Kokoris SI, Kyrtsonis MC, Tsaftaridis P, Karkantaris C, Anargyrou K, Boutsis DE, Variamis E, Michalopoulos T, Boussiotis VA, Panayiotidis P, Papavassiliou C, Pangalis GA.
    Int J Radiat Oncol Biol Phys; 2004 Jul 01; 59(3):765-81. PubMed ID: 15183480
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group.
    Chua DT, Sham JS, Choy D, Lorvidhaya V, Sumitsawan Y, Thongprasert S, Vootiprux V, Cheirsilpa A, Azhar T, Reksodiputro AH.
    Cancer; 1998 Dec 01; 83(11):2270-83. PubMed ID: 9840526
    [Abstract] [Full Text] [Related]

  • 20. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.
    Josting A, Nogová L, Franklin J, Glossmann JP, Eich HT, Sieber M, Schober T, Boettcher HD, Schulz U, Müller RP, Diehl V, Engert A.
    J Clin Oncol; 2005 Mar 01; 23(7):1522-9. PubMed ID: 15632410
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.